The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation

• Published in: Genes & development Vol. 30; no. 7; pp. 786 - 797
• Main Authors: Aylon, Yael, Gershoni, Anat, Rotkopf, Ron, Biton, Inbal E., Porat, Ziv, Koh, Anna P., Sun, Xiaochen, Lee, Youngmin, Fiel, Maria-Isabel, Hoshida, Yujin, Friedman, Scott L., Johnson, Randy L., Oren, Moshe
• Format: Journal Article
• Language: English
• Published: United States Cold Spring Harbor Laboratory Press 01.04.2016
• Subjects: Animals; Cholesterol, Dietary - pharmacology; Fatty Liver - enzymology; Fatty Liver - genetics; Gene Deletion; Gene Expression Regulation - genetics; Hep G2 Cells; Homeostasis - genetics; Humans; Liver - drug effects; Liver - enzymology; Mice, Knockout; Protein Binding; Protein-Serine-Threonine Kinases - genetics; Protein-Serine-Threonine Kinases - metabolism; Research Paper; Signal Transduction; Sterol Regulatory Element Binding Protein 2 - genetics; Sterol Regulatory Element Binding Protein 2 - metabolism; Tumor Suppressor Protein p53 - genetics; Tumor Suppressor Protein p53 - metabolism; Tumor Suppressor Proteins - genetics; Tumor Suppressor Proteins - metabolism; Lats; YAP; cholesterol; fatty liver; Hippo; p53

The Hippo signaling pathway is a major regulator of organ size. In the liver, Hippo pathway deregulation promotes hyperplasia and hepatocellular carcinoma primarily through hyperactivation of its downstream effector, YAP. The LATS2 tumor suppressor is a core member of the Hippo pathway. A screen for...